Living on the edge with too many mouths to feed: Why dopamine neurons die

Movement Disorders

Volumn 27, Issue 12, 2012, Pages 1478-1483

  Bolam, J Paul ^a   Pissadaki, Eleftheria K ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Dopamine neurons; Energy; Neurodegeneration; Parkinson's

Indexed keywords

ARTICLE; CELL STRUCTURE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GLOBUS PALLIDUS; HUMAN; NERVE CELL NECROSIS; NERVE FIBER; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SYNAPSE; VENTRAL TEGMENTUM;

ANIMALS; AXONS; CELL DEATH; DOPAMINERGIC NEURONS; HUMANS; PARKINSON DISEASE; SUBSTANTIA NIGRA; SYNAPSES;

EID: 84867745060     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25135     Document Type: Article

References (57)

1. Martin I, Dawson VL, Dawson TM. The impact of genetic research on our understanding of Parkinson's disease. Prog Brain Res 2010; 183: 21-41.
2. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7: 97-109.
3. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007; 30: 244-250.
4. Gasser T. Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects. Prog Brain Res 2010; 183: 3-20.
5. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010; 16: 653-661.
6. Surmeier DJ, Guzman JN, Sanchez-Padilla J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium 2010; 47: 175-182.
7. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, Surmeier DJ. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010; 468: 696-700.
8. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA. What causes the death of dopaminergic neurons in Parkinson's disease? Prog Brain Res 2010; 183: 59-77.
9. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007; 447: 1081-1086.
10. Van Laar VS, Dukes AA, Cascio M, Hastings TG. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis 2008; 29: 477-489.
11. Van Laar VS, Mishizen AJ, Cascio M, Hastings TG. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis 2009; 34: 487-500.
12. Berman SB Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999; 73: 1127-1137.
13. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988; 334: 345-348.
14. Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, Fornai F. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 2000; 24: 655-668.
15. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134.
16. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249( Suppl 3): III/1-5.
17. Meredith GE, Halliday GM, Totterdell S. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord 2004; 10: 191-202.
18. Langston JW. MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life Sci 1985; 36: 201-206.
19. Lammel S, Hetzel A, Hackel O, Jones I, Liss B, Roeper J. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 2008; 57: 760-773.
20. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003; 179: 9-16.
21. Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 2009; 36: 96-102.
22. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301-1306.
23. Moss J, Bolam JP. A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals. J Neurosci 2008; 28: 11221-11230.
24. Moss J, Bolam JP. The relationship between dopaminergic axons and glutamatergic synapses in the striatum: structural considerations. In: Iversen LL, Iversen SD, Dunnett SB, Björklund A, eds. Dopamine Handbook. New York; Oxford University Press; 2010: 49-59.
25. Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, Arai R, Kaneko T. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci 2009; 29: 444-453.
26. Andén NE, Fuxe K, Hamberger B, Hökfelt T. A quantitative study on the nigro-neostriatal dopamine neuron system in the rat. Acta Physiol Scand 1966; 67: 306-312.
27. Björklund A, Lindvall O. Dopamine-containing sytems in the CNS. In: Björklund A, Hökfelt T, eds. Handbook of Chemical Neuroanatomy. Amsterdam: Elsevier; 1984: 55-122.
28. Wickens J, Arbuthnott GW Strutural and functional interactions in the striatum at the receptor level. In: Dunnett SB, Bentivoglio M, Björklund A, Hökfelt T, eds. Handbook of Chemical Neuroanatomy. Amsterdam: Elsevier; 2005: 199-236.
29. Nair-Roberts RG, Chatelain-Badie SD, Benson E, White-Cooper H, Bolam JP, Ungless MA. Stereological estimates of dopaminergic, GABAergic, and glutamatergic neurons in the ventral tegmental area, substantia nigra, and retrorubral field in the rat. Neuroscience 2008; 152: 1024-1031.
30. Oorschot DE. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J Comp Neurol 1996; 366: 580-599.
31. Bevan MD, Booth PAC, Eaton SA, Bolam JP. Selective innervation of neostriatal interneurons by a subclass of neuron in the globus pallidus of the rat. J Neurosci 1998; 18: 9438-9452.
32. Kawaguchi Y, Wilson CJ, Emson PC. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci 1990; 10: 3421-3438.
33. Kita H, Kitai ST. The morphology of globus pallidus projection neurons in the rat: an intracellular staining study. Brain Res 1994; 636: 308-319.
34. Tepper JM, Bolam JP. Functional diversity and specificity of neostriatal interneurons. Curr Opin Neurobiol 2004; 14: 685-692.
35. Wu Y, Richard S, Parent A. The organization of the striatal output system: a single-cell juxtacellular labeling study in the rat. Neurosci Res 2000; 38: 49-62.
36. Furuta T, Tomioka R, Taki K, Nakamura K, Tamamaki N, Kaneko T. In vivo transduction of central neurons using recombinant Sindbis virus: Golgi-like labeling of dendrites and axons with membrane-targeted fluorescent proteins. J Histochem Cytochem 2001; 9: 1497-1508.
37. Fujiyama F, Sohn J, Nakano T, Furuta T, Nakamura KC, Matsuda W, Kaneko T. Exclusive and common targets of neostriatofugal projections of rat striosome neurons: a single neuron-tracing study using a viral vector. Eur J Neurosci 2011; 33: 668-677.
38. Ohno S, Kuramoto E, Furuta T, et al. A morphological analysis of thalamocortical axon fibers of rat posterior thalamic nuclei: a single neuron tracing study with viral vectors. Cerebral Cortex 2011 Dec 20. doi: 10.1093/cercor/bhr356.
39. Prensa L, Parent A. The nigrostriatal pathway in the rat: a single-axon study of the relationship between dorsal and ventral tier nigral neurons and the striosome/matrix striatal compartments. J Neurosci 2001; 21: 7247-7260.
40. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 2001; 21: 1133-1145.
41. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122: 1437-1448.
42. Khaliq ZM, Bean BP. Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J Neurosci 2010; 30: 7401-7413.
43. Yin D, Valles FE, Fiandaca MS, Forsayeth J, Larson P, Starr P, Bankiewicz KS. Striatal volume differences between non-human and human primates. J Neurosci Methods 2009; 176: 200-205.
44. Hardman CD, Henderson JM, Finkelstein DI, Horne MK, Paxinos G, Halliday GM. Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J Comp Neurol 2002; 445: 238-255.
45. Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci 1991; 14: 21-27.
46. Garcia-Cabezas MA, Martinez-Sanchez P, Sanchez-Gonzalez MA, Garzon M, Cavada C. Dopamine innervation in the thalamus: monkey versus rat. Cereb Cortex 2009; 19: 424-434.
47. Pissadaki EK, Bolam, JP. Signal propagation and metabolic efficiency in the axons of SNc dopamine neurons. IBAGS X June 20-24, 2010, Long Branch, NJ.
48. Elstner M, Morris CM, Heim K, et al. Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropath 2011; 122: 75-86.
49. Wellstead P, Cloutier M. An energy systems approach to Parkinson's disease. Wiley Interdiscip Rev Syst Biol Med 2011; 3: 1-6.
50. Kim-Han JS, Antenor-Dorsey JA, O'Malley KL. The Parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J Neurosci 2011; 31: 7212-7221.
51. Burke RE, O'Malley K. Axon degeneration in Parkinson's disease. Exp Neurol 2012 Jan 18. doi: 10.1016/j.expneurol.2012.01.011.
52. Patel NK, Gill SS. GDNF delivery for Parkinson's disease. Acta Neurochir Suppl 2007; 97: 135-154.
53. Rosenblad C, Kirik D, Björklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp Neurol 2000; 161: 503-516.
54. Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 1999; 11: 1554-1566.
55. Welberg L. SNc neurons' Achilles heel. Nature Rev Neurosci 2011; 12: 6-7.
56. Kincaid AE, Zheng T, Wilson CJ. Connectivity and convergence of single corticostriatal axons. J Neurosci 1998; 18: 4722-4731.
57. Lacey CJ, Boyes J, Gerlach O, Chen L, Magill PJ, Bolam JP. GABA(B) receptors at glutamatergic synapses in the rat striatum. Neuroscience 2005; 136: 1083-1095.